Patients with brain metastases tended to have a worse PFS benefit (PFS = 15.2, 95% CI = 12.1–21.4 months) than those without brain metastases (PFS = 19.1, 95% CI = 15.2–23.5 months) in EGFR‐mutation NSCLC patients in the FLAURA study.44 This evidence concerns the gene EGFR and non-small cell lung carcinoma.